# Novel GLP-1 Cut Heavy Drinking Days in Alcohol Use Disorder

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/meetingcoverage/aasld/123855) · 2026-11-12 · Medicine
Page: https://themorning.science/story/novel-glp-1-cut-heavy-drinking-days-in-alcohol-use-disorder-ac3db0a27ae44bce
Kind: research · Impact: medium

## In brief

- The investigational glucagon/GLP-1 dual receptor agonist pemvidutide significantly reduced heavy drinking days per week in patients with moderate-to-severe alcohol use disorder.
- The result comes from the phase II RECLAIM trial, as reported by MedPage Today from AASLD meeting coverage.

## Why it matters

Heavy drinking days are a core outcome in alcohol use disorder, so a significant reduction in a phase II trial signals a possible new drug approach for clinicians and researchers, though it is not yet an approved treatment.

## Coverage

- [Novel GLP-1 Cut Heavy Drinking Days in Alcohol Use Disorder](https://www.medpagetoday.com/meetingcoverage/aasld/123855) — MedPageToday.com - medical news for physicians, 2026-11-12

Tags: alcohol use disorder, glp-1, pemvidutide, clinical trial, addiction medicine

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science